What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer Inc (NYSE:PFE) shares are moving lower Wednesday alongside several pharmaceutical giants after President Donald Trump ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...